

Prednisolone

Newborn Use Only

2024

Alert	Routine use of prednisolone for prevention of chronic lung disease is not recommended.
Indication	Treatment of severe bronchopulmonary dysplasia ≥ 36 weeks gestation
Action	<ul style="list-style-type: none"> • Predominantly glucocorticoid effects with minimal mineralocorticoid effects • Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. • suppresses the immune system by reducing activity and volume of the lymphatic system
Drug Type	Synthetic glucocorticoid.
Trade Name	Redipred Predmix (not first choice due to propylene glycol content)
Presentation	Liquid: 5mg/mL (recommended) Note: Prednisolone tablets may be used if there is stock availability issues of the liquid products. Contact local pharmacy department for appropriate preparation using tablets.
Dose	<p>NOTE: It is highly recommended to consult paediatric respiratory specialist before commencing prednisolone therapy.</p> <p>14-day ORAL regimen course¹ Day 1 to Day 5 (5 days): 1 mg/kg/dose 12 hourly, Day 6 to Day 8 (3 days): 1 mg/kg/dose 24 hourly, Day 9 (1 day): No dose Day 10 to Day 14 (5 days): 1 mg/kg/dose 48 hourly</p>
Dose adjustment	Therapeutic hypothermia – Not applicable. ECMO- Not applicable. Hepatic impairment – Metabolised in liver, but no specific dose adjustment is suggested. Renal impairment – No dose adjustment.
Route	Oral/OGT/NGT
Preparation	N/A
Administration	Administer undiluted with feeds
Monitoring	Blood pressure, weight, BGL, electrolytes, bone mineral density, haemoglobin, signs of infection
Contraindications	Uncontrolled infections Systemic fungal infections Known hypersensitivity to prednisolone or prednisone
Precautions	Adrenal suppression Immunosuppression Metabolic bone disease
Drug Interactions	Phenobarbital increases prednisolone's metabolism and may reduce its activity
Adverse Reactions	Vomiting, abdominal distension, diarrhoea Increased appetite Agitation Hyperglycaemia Hypokalaemia Hypertension Reduced growth (long term treatment) Osteopenia (long term treatment) Reduced wound healing Sodium and water retention
Overdose	For further information, contact the Poisons Information Centre on 131 126 (Australia).
Compatibility	Not applicable.
Incompatibility	Not applicable.
Stability	Discard commercial liquids 4 weeks after opening
Storage	Redipred brand store at room temperature below 25°C Predmix brand store refrigerated at 2–8°C

Excipients	<p>Redipred: Sorbitol solution (70%) non-crystallising, disodium edetate, monobasic sodium phosphate, dibasic sodium phosphate, methyl hydroxybenzoate, propyl hydroxybenzoate, nature identical raspberry flavour 08-3326 and water-purified.</p> <p>Predmix: Propylene glycol, methyl hydroxybenzoate, propyl hydroxybenzoate, dibasic sodium phosphate dodecahydrate, monobasic sodium phosphate, disodium edetate and water-purified.</p>
Special Comments	Immunise one month before starting or at least one month after ceasing corticosteroids.
Evidence	<p>Background</p> <p>Bronchopulmonary dysplasia (BPD) in preterm infants is associated with delayed brain maturation and diffuse white matter anomalies that are associated with increased risk of neurodevelopmental impairment.² Dexamethasone has been acknowledged in multiple trials as a long-acting glucocorticoid that can be used to prevent or treat developing BPD. Methylprednisolone and prednisolone are alternate steroids, and there is emerging evidence to support their use in some infants at high risk of BPD or established BPD. Both prednisolone and methylprednisolone have been safely used for other pulmonary diseases, primarily within the paediatric asthma population, but there is a paucity of available evidence for their use in the neonatal population.</p> <p>Efficacy</p> <p>There are no published studies on commencement of dexamethasone for treatment of BPD in preterm infants beyond 36 weeks gestation. There are 3 retrospective studies reporting on the efficacy of prednisolone/methylprednisolone for severe BPD in preterm neonates beyond 36 weeks corrected gestation.</p> <p><u>A single centre retrospective cohort study by Bhandari et al</u>, assessed 385 infants of whom 131 (34%) received oral prednisolone to support weaning from oxygen at 36 weeks postmenstrual age.¹ 63% of these infants were deemed responsive to oral prednisolone therapy and able to be weaned from oxygen, with lower pulmonary acuity scores than those infants non-responsive to treatment. Predictive responsiveness to oral prednisolone therapy identified a capillary PCO₂ value of < 48.5 mmHg had a sensitivity of 50% and specificity of 89.7%, with positive and negative predictive values of 89.1% and 51.8%, respectively. The dose of oral prednisolone used in Bhandari regimen was 2 mg/kg/day in 2 divided doses for 5 days, then 1 mg/kg/day daily for 3 days, and then 1 mg/kg/dose every other day for 3 doses. It was noted however that many of this group may also have received treatment with dexamethasone prior to commencement of prednisolone.</p> <p><u>A single-centre retrospective cohort study by Linafelter et al</u>, identified 43 infants with a mean gestational age of 26 weeks, who were treated with an extended course (≥ 30 days) of prednisolone for severe BPD, using pulmonary severity score (PSS) as a primary outcome measure. The average age at start of prednisolone treatment was 42.5 ± 5.9 weeks; while the median duration and median cumulative dose of prednisolone therapy were 67 (IQR 57–107) days and 61.3 (IQR 39.9–93.3) mg/kg, respectively.³ PSS decreased after 1 week of prednisolone therapy (mean difference, 0.19; 95% CI, 0.01 to 0.37; p = 0.03). No further reduction in PSS was noted despite continued treatment. Length z-scores decreased after 4 weeks of continued treatment (mean difference 0.6; 95% CI 0.01 to 1.1; P = 0.04), while weight and head circumference did not change.³</p> <p><u>Another retrospective study by Liviskie et al</u>, described the use of prednisolone for late treatment of pulmonary disease in infants with established BPD, after the first month of life. This study identified 34 patients where prednisolone treatment was initiated at a mean postmenstrual age of 41.7 weeks. Typically, 1-2 mg/kg/d and weaned by 0.5 every 5-7 days (>30 day course). A significant decrease in PSS was observed (p<0.001) without rebound following discontinuation of treatment.⁴ This study, conversely, did not identify any significant impact on anthropometric measures.</p> <p>Safety of dexamethasone versus prednisolone or methylprednisolone</p> <p>A secondary analysis of a multi-centre randomised controlled trial (Preterm Erythropoietin Neuroprotection – PENUT trial) reported 2-year neurodevelopmental outcomes in extremely preterm infants treated with dexamethasone, methylprednisolone, and prednisolone. The study identified an association between reduced BSID III scores and > 14 days treatment with dexamethasone. The median (IQR) start day was 29 (20-44) days for dexamethasone and 53 (30-90) days for prednisolone or methylprednisolone. The median (IQR) total days of exposure was 10 (5-15) days for dexamethasone and 13 (6-25) days for prednisolone or methylprednisolone. The median (IQR) cumulative dose of</p>

dexamethasone was 1.3 (0.9-2.8) mg/kg. After adjusting for potential confounders, treatment with dexamethasone for longer than 14 days was associated with worse neurodevelopmental outcomes. The same finding was not identified in the methylprednisolone and prednisolone group however the numbers in this cohort were small (n=99) and brains were more mature at the time of exposure.⁵ This subgroup analysis of the PENUT trial demonstrated no long term neurologic complications from prednisolone use starting on average at day 50 of life and continued for an average of 13 days. There were also some benefits on neurodevelopment for the infants treated with 8 to 14 days of prednisolone.⁵

ANMF consensus: Secondary analysis of PENUT trial reported worse neurodevelopmental outcomes with long courses of dexamethasone and no such effect was seen with short courses of either prednisolone or methylprednisolone. However, subgroup analyses of RCTs carry limitations such as poor definitions, low statistical power, and inflated type I error due to multiple hypotheses testing. Similarly a long course (>30 days) of prednisolone was shown to decrease length z-scores.³ A short course of oral prednisolone may be considered in weaning off respiratory support in preterm infants closer to term or post term with severe bronchopulmonary dysplasia. It is highly recommended to consult paediatric respiratory specialist before commencing prednisolone therapy.

Pharmacokinetics

Prednisolone is readily absorbed from the gastrointestinal tract. It is mostly metabolised in liver and excreted in urine.

Safety

No specific adverse events have been reported with short courses of prednisolone in the above mentioned studies. However, extended course of prednisolone>30 days was associated with reduced length z scores.³

Vaccines post prednisolone: Australian Immunisation handbook has made the following recommendations for infants and children weighing ≤10 Kg:⁶

Prednisone-equivalent dose	Duration of therapy	Potential timing of vaccination
<1 mg/kg/day	<30 days	Anytime during therapy
<2 mg/kg/day	<14 days	Anytime during therapy
<2 mg/kg/day	14-28 days	Immunise 1 month before starting corticosteroids or at least 1 month after stopping corticosteroids. Alternatively, person may be able to receive live vaccines at any time during therapy, but only after seeking expert advice.
≥2 mg/kg/day	<14 days	Immunise 1 month before starting corticosteroids or any time after stopping corticosteroids.
≥2 mg/kg/day	14-28 days	Immunise 1 month before starting corticosteroids or at least 1 month after stopping corticosteroids.

Note: 1 mg prednisone = 1 mg prednisolone = 0.1 mg dexamethasone.

Practice points

References

1. Bhandari A, Schramm CM, Kimble C, Pappagallo M, Hussain N. Effect of a short course of prednisolone in infants with oxygen-dependent bronchopulmonary dysplasia. *Pediatrics*. 2008;121(2):e344-e9.
2. Anderson PJ, Doyle LW, editors. Neurodevelopmental outcome of bronchopulmonary dysplasia. *Semin Perinatol*; 2006: Elsevier.
3. Linafelter A, Cuna A, Liu C, Quigley A, Truog WE, Sampath V, et al. Extended course of prednisolone in infants with severe bronchopulmonary dysplasia. *Early human development*. 2019;136:1-6.
4. Liviskie C, Vesoulis Z, Zeller B, Rao R, McPherson C. Respiratory effects of prolonged prednisolone use in infants with evolving and established Bronchopulmonary dysplasia. *Early Human Development*. 2021;156:105344.

	<p>5. Puia-Dumitrescu M, Wood TR, Comstock BA, Law JB, German K, Perez KM, et al. Dexamethasone, prednisolone, and methylprednisolone use and 2-year neurodevelopmental outcomes in extremely preterm infants. <i>JAMA Network Open</i>. 2022;5(3):e221947-e.</p> <p>6. Australian Immunisation Handbook. Accessed online on 7 March 2024.</p>
--	--

Version/Number	Date
Version 1.0	28/03/2024
Current 1.0 (minor errata)	11/07/2024
Review	28/03/2029

Authors of the current version

Original author/s	Srinivas Bolisetty, Rebecca Barzegar
Evidence Review	Srinivas Bolisetty, Rebecca Barzegar
Expert review	Louisa Owens, Saikiran Gopalakaje
Nursing Review	Bryony Malloy, Eszter Jozsa
Pharmacy Review	Rebecca O’Grady, Michelle Jenkins
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, Rebecca Barzegar, Martin Kluckow, Mohammad Irfan Azeem, Thao Tran, Susanah Brew, Simarjit Kaur, Helen Huynh, Stephanie Halena, Benjamin Emerson-Parker, Renae Gengaroli, Kerryn Houghton
Final editing	Srinivas Bolisetty
Electronic version	Thao Tran, Helen Huynh, Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty

Citation for the current version

Bolisetty S, Barzegar R, O’Grady R, Jenkins M, Malloy B, Jozsa E, Azeem MI, Phad N, Mehta B, Kluckow M, Tran T, Huynh H, Halena S, Brew S, Kaur S, Houghton K, Sronic N, Gengaroli R, Chen C, Owens L, Gopalakaje S, Callander I. Prednisolone. Consensus formulary by the Australasian Neonatal Medicines Formulary group. Version 1, dated 28 March 2024. www.anmfonline.org